RU2011133891A - СПОСОБ ЛЕЧЕНИЯ АСТМЫ (ВАРИАНТЫ) И СПОСОБ СНИЖЕНИЯ РИСКА РАЗВИТИЯ ИНФЕКЦИЙ ПОСРЕДСТВОМ β-ГИДРОКСИ-β-МЕТИЛБУТИРАТА - Google Patents
СПОСОБ ЛЕЧЕНИЯ АСТМЫ (ВАРИАНТЫ) И СПОСОБ СНИЖЕНИЯ РИСКА РАЗВИТИЯ ИНФЕКЦИЙ ПОСРЕДСТВОМ β-ГИДРОКСИ-β-МЕТИЛБУТИРАТА Download PDFInfo
- Publication number
- RU2011133891A RU2011133891A RU2011133891/15A RU2011133891A RU2011133891A RU 2011133891 A RU2011133891 A RU 2011133891A RU 2011133891/15 A RU2011133891/15 A RU 2011133891/15A RU 2011133891 A RU2011133891 A RU 2011133891A RU 2011133891 A RU2011133891 A RU 2011133891A
- Authority
- RU
- Russia
- Prior art keywords
- methylbutyrate
- hydroxy
- cytokines
- interleukin
- type
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pediatric Medicine (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
1. Способ лечения астмы у индивидуума, характеризующейся дисбалансом содержания цитокинов первого и второго типов, который включает введение индивидууму β-гидрокси-β-метилбутирата в количестве, эффективном для модуляции дисбаланса продукции цитокинов первого и второго типов.2. Способ по п.1, в котором отношение содержания цитокинов первого типа к содержанию цитокинов второго типа возрастает в результате введения β-гидрокси-β-метилбутирата.3. Способ по п.2, в котором содержание цитокинов первого типа возрастает без повышения содержания цитокинов второго типа.4. Способ по п.2, в котором эффективное количество β-гидрокси-β-метилбутирата находится в пределах от приблизительно 0,5 до приблизительно 10 г в день.5. Способ по п.2, в котором β-гидрокси-β-метилбутират вводится в составе питательного продукта, который дополнительно содержит по меньшей мере один жир и/или белок и/или углевод.6. Способ по п.2, в котором цитокины типа 1 выбраны из группы, включающей интерферон y, интерлейкин 2 и интерлейкин 12, а цитокины типа 2 выбраны из группы, включающей интерлейкин 4, интерлейкин 5, интерлейкин 13 и интерлейкин 10.7. Способ по п.1, в котором количество β-гидрокси-β-метилбутирата является эффективным для предотвращения уменьшения значения FEV.8. Способ по п.1, в котором количество β-гидрокси-β-метилбутирата является эффективным для поддержания базового значения FEVвыше 80%.9. Способ по п.1, в котором цитокины типа 1 представляют собой интерфероны или интерлейкин 2, а цитокины типа 2 представляют собой интерлейкин 4.10. Способ лечения астмы у индивидуума, относящегося к группе риска в отношении развития астмы, включающий введение указанному индивид
Claims (15)
1. Способ лечения астмы у индивидуума, характеризующейся дисбалансом содержания цитокинов первого и второго типов, который включает введение индивидууму β-гидрокси-β-метилбутирата в количестве, эффективном для модуляции дисбаланса продукции цитокинов первого и второго типов.
2. Способ по п.1, в котором отношение содержания цитокинов первого типа к содержанию цитокинов второго типа возрастает в результате введения β-гидрокси-β-метилбутирата.
3. Способ по п.2, в котором содержание цитокинов первого типа возрастает без повышения содержания цитокинов второго типа.
4. Способ по п.2, в котором эффективное количество β-гидрокси-β-метилбутирата находится в пределах от приблизительно 0,5 до приблизительно 10 г в день.
5. Способ по п.2, в котором β-гидрокси-β-метилбутират вводится в составе питательного продукта, который дополнительно содержит по меньшей мере один жир и/или белок и/или углевод.
6. Способ по п.2, в котором цитокины типа 1 выбраны из группы, включающей интерферон y, интерлейкин 2 и интерлейкин 12, а цитокины типа 2 выбраны из группы, включающей интерлейкин 4, интерлейкин 5, интерлейкин 13 и интерлейкин 10.
7. Способ по п.1, в котором количество β-гидрокси-β-метилбутирата является эффективным для предотвращения уменьшения значения FEV1.
8. Способ по п.1, в котором количество β-гидрокси-β-метилбутирата является эффективным для поддержания базового значения FEV1 выше 80%.
9. Способ по п.1, в котором цитокины типа 1 представляют собой интерфероны или интерлейкин 2, а цитокины типа 2 представляют собой интерлейкин 4.
10. Способ лечения астмы у индивидуума, относящегося к группе риска в отношении развития астмы, включающий введение указанному индивидууму эффективного количества β-гидрокси-β-метилбутирата.
11. Способ по п.10, в котором β-гидрокси-β-метилбутират вводят в составе питательного продукта, который дополнительно содержит по меньшей мере один жир и/или белок и/или углевод.
12. Способ по п.11, в котором эффективное количество β-гидрокси-β-метилбутирата находится в пределах от приблизительно 0,5 до приблизительно 10 г в день.
13. Способ снижения риска развития инфекций у индивидуума пожилого возраста, относящегося к группе риска в отношении указанных инфекций, который включает введение указанному индивидууму эффективного количества β-гидрокси-β-метилбутирата.
14. Способ по п.13, в котором β-гидрокси-β-метилбутират вводят в составе питательного продукта, который дополнительно содержит по меньшей мере один жир и/или белок и/или углевод.
15. Способ по п.14, в котором эффективное количество β-гидрокси-β-метилбутирата находится в пределах от приблизительно 0,5 до приблизительно 10 г в день.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75225305P | 2005-12-19 | 2005-12-19 | |
| US60/752,253 | 2005-12-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008129605/15A Division RU2469719C2 (ru) | 2005-12-19 | 2006-12-19 | СПОСОБ ЛЕЧЕНИЯ АЛЛЕРГИИ, СПОСОБ ЛЕЧЕНИЯ АСТМЫ, СПОСОБ СНИЖЕНИЯ РИСКА РАЗВИТИЯ ИНФЕКЦИИ И СПОСОБ ЛЕЧЕНИЯ СОСТОЯНИЯ, ХАРАКТЕРИЗУЮЩЕГОСЯ ДИСБАЛАНСОМ СОДЕРЖАНИЯ ЦИТОКИНОВ ТИПОВ 1 И 2, ПОСРЕДСТВОМ β-ГИДРОКСИ-β-МЕТИЛБУТИРАТА |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011133891A true RU2011133891A (ru) | 2013-02-20 |
Family
ID=38066532
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008129605/15A RU2469719C2 (ru) | 2005-12-19 | 2006-12-19 | СПОСОБ ЛЕЧЕНИЯ АЛЛЕРГИИ, СПОСОБ ЛЕЧЕНИЯ АСТМЫ, СПОСОБ СНИЖЕНИЯ РИСКА РАЗВИТИЯ ИНФЕКЦИИ И СПОСОБ ЛЕЧЕНИЯ СОСТОЯНИЯ, ХАРАКТЕРИЗУЮЩЕГОСЯ ДИСБАЛАНСОМ СОДЕРЖАНИЯ ЦИТОКИНОВ ТИПОВ 1 И 2, ПОСРЕДСТВОМ β-ГИДРОКСИ-β-МЕТИЛБУТИРАТА |
| RU2011133891/15A RU2011133891A (ru) | 2005-12-19 | 2011-08-12 | СПОСОБ ЛЕЧЕНИЯ АСТМЫ (ВАРИАНТЫ) И СПОСОБ СНИЖЕНИЯ РИСКА РАЗВИТИЯ ИНФЕКЦИЙ ПОСРЕДСТВОМ β-ГИДРОКСИ-β-МЕТИЛБУТИРАТА |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008129605/15A RU2469719C2 (ru) | 2005-12-19 | 2006-12-19 | СПОСОБ ЛЕЧЕНИЯ АЛЛЕРГИИ, СПОСОБ ЛЕЧЕНИЯ АСТМЫ, СПОСОБ СНИЖЕНИЯ РИСКА РАЗВИТИЯ ИНФЕКЦИИ И СПОСОБ ЛЕЧЕНИЯ СОСТОЯНИЯ, ХАРАКТЕРИЗУЮЩЕГОСЯ ДИСБАЛАНСОМ СОДЕРЖАНИЯ ЦИТОКИНОВ ТИПОВ 1 И 2, ПОСРЕДСТВОМ β-ГИДРОКСИ-β-МЕТИЛБУТИРАТА |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US8778992B2 (ru) |
| EP (2) | EP1968564B1 (ru) |
| JP (2) | JP5227182B2 (ru) |
| CN (2) | CN102225060A (ru) |
| AU (1) | AU2006331950A1 (ru) |
| BR (1) | BRPI0620083A2 (ru) |
| CA (1) | CA2632262C (ru) |
| CR (1) | CR10085A (ru) |
| EC (1) | ECSP088539A (ru) |
| ES (2) | ES2548432T3 (ru) |
| MY (1) | MY180733A (ru) |
| NZ (2) | NZ568611A (ru) |
| RU (2) | RU2469719C2 (ru) |
| SV (1) | SV2009002948A (ru) |
| TW (1) | TWI424840B (ru) |
| WO (1) | WO2007075605A2 (ru) |
| ZA (1) | ZA200805297B (ru) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050215640A1 (en) | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
| NZ568611A (en) | 2005-12-19 | 2011-11-25 | Abbott Lab | Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type 1 and type 2 cytokine production |
| US9404924B2 (en) | 2008-12-04 | 2016-08-02 | Massachusetts Institute Of Technology | Method of performing one-step, single cell RT-PCR |
| JP5675638B2 (ja) * | 2008-12-04 | 2015-02-25 | マサチューセッツ インスティテュート オブ テクノロジー | アレルギー反応を診断するための方法 |
| US9259430B2 (en) | 2008-12-09 | 2016-02-16 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| DK2381784T3 (en) | 2008-12-09 | 2018-10-22 | Metabolic Tech Inc | Nutritional intervention to improve muscle function and strength |
| US11173167B2 (en) | 2008-12-09 | 2021-11-16 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| US9707241B2 (en) | 2008-12-09 | 2017-07-18 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| US9770424B2 (en) | 2008-12-09 | 2017-09-26 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| US9539224B2 (en) | 2008-12-09 | 2017-01-10 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| PL2448425T3 (pl) * | 2009-07-03 | 2019-02-28 | Nutreco Nederland B.V. | Pasza dla zwierząt, albo żywność dla ludzi, polepszająca właściwości bariery ochronnej jelit |
| TWI508670B (zh) * | 2010-01-29 | 2015-11-21 | Abbott Lab | 包含經噴霧乾燥之ｈｍｂ的營養粉末 |
| EP2528457B1 (en) * | 2010-01-29 | 2015-01-14 | Abbott Laboratories | Plastic packaged nutritonal liquids comprising hmb |
| AU2011210691A1 (en) | 2010-01-29 | 2012-07-12 | Abbott Laboratories | Nutritional emulsions comprising calcium HMB |
| AU2011210682A1 (en) | 2010-01-29 | 2012-07-05 | Abbott Laboratories | Aseptically packaged nutritional liquids comprising HMB |
| US9693577B2 (en) | 2010-01-29 | 2017-07-04 | Abbott Laboratories | Method of preparing a nutritional powder comprising spray dried HMB |
| JP5734314B2 (ja) * | 2010-01-29 | 2015-06-17 | アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ | カルシウムｈｍｂおよび可溶性タンパク質を含む栄養エマルション |
| TWI526161B (zh) * | 2010-06-10 | 2016-03-21 | 亞培公司 | 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液 |
| US9326956B2 (en) | 2011-02-17 | 2016-05-03 | Abbott Laboratories | Methods for improving brain development and cognitive function using beta-hydroxy-beta methylbutyrate |
| CN102524332A (zh) * | 2011-12-19 | 2012-07-04 | 北京康比特体育科技股份有限公司 | 一种减肥压缩饼干及其制备方法 |
| MX2014011296A (es) * | 2012-03-19 | 2014-10-17 | Abbott Lab | Acido beta-hidroxi-beta-metilbutirico para mejorar la tolerancia a la glucosa. |
| WO2013188258A1 (en) * | 2012-06-11 | 2013-12-19 | Abbott Laboratories | Use of hmb to improve health outcomes for hospitalized patients |
| MX2015003498A (es) * | 2012-09-17 | 2015-06-04 | Abbott Lab | Composiciones que contienen acido beta-hidroxi-beta-metilbutirico y usos de las mismas. |
| MX2015012821A (es) | 2013-03-14 | 2016-05-31 | Abbott Lab | Tratamiento de resistencia a la insulina asociado con la inactividad fisica prolongada. |
| US20140272000A1 (en) * | 2013-03-14 | 2014-09-18 | Metabolic Technologies, Inc. | Liquids and Foodstuffs Containing beta-hydroxy-beta-methylbutyrate (HMB) in the Free Acid Form and Methods of Manufacturing or Producing the Same |
| US20160037815A1 (en) * | 2013-03-15 | 2016-02-11 | Abbott Laboratories | Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, casein phosphopeptide, and protein |
| WO2017049093A1 (en) | 2015-09-16 | 2017-03-23 | Metabolic Technologies, Inc. | COMPOSITIONS AND METHODS OF USE OF β-HYDROXY-β-METHYLBUTYRATE (HMB) FOR ENHANCING RECOVERY FROM SOFT TISSUE TRAUMA |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| CN111295187A (zh) | 2017-08-14 | 2020-06-16 | 胺细拉健康公司 | 用于治疗肝脏疾病的氨基酸组合物 |
| EP3810123A1 (en) | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
| JP7156683B2 (ja) * | 2018-09-28 | 2022-10-19 | 株式会社東洋新薬 | 経口組成物 |
| US20230263751A1 (en) * | 2020-06-15 | 2023-08-24 | Metabolic Technologies, LLC | Compositions and Methods of Use of beta-hydroxy-beta-methylbutyrate (HMB) and Chemotherapy Agents |
Family Cites Families (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3408210A (en) * | 1965-06-14 | 1968-10-29 | Wilbert A. Heyman | Dehydration of foods |
| US3542560A (en) * | 1967-12-06 | 1970-11-24 | American Home Prod | Infant formula with fat composition like human milk |
| GB1446965A (en) * | 1974-02-14 | 1976-08-18 | Agricultural Vegetable Prod | Preparation of food products |
| US4104290A (en) * | 1975-02-07 | 1978-08-01 | H.L.S. Ltd., Industrial Engineering Company | Process for separating oils and fats into liquid and solid fractions |
| US4311645A (en) * | 1980-03-24 | 1982-01-19 | Hoffmann-La Roche Inc. | Synthesis of SRS-active compounds |
| US4866040A (en) * | 1986-01-06 | 1989-09-12 | Alfred Stracher | Aminocarnitine directed pharmaceutical agents |
| US4742081A (en) * | 1986-01-06 | 1988-05-03 | Alfred Stracher | Carnitine coupled pharmaceutical agents |
| EP0367724B1 (en) | 1988-10-31 | 1993-02-10 | Sandoz Nutrition Ltd. | Improvements in or relating to organic compounds |
| US5000975A (en) * | 1988-12-29 | 1991-03-19 | American Home Products Corporation | Randomized palm oil fat composition for infant formulas |
| CA2010511A1 (en) | 1989-03-01 | 1990-09-01 | Roberto L. Ceriani | Method of enhancing cancer therapy by administration of unsaturated fatty acids |
| US5457130A (en) * | 1989-03-20 | 1995-10-10 | Cancer Research Campaign Technology Limited | Eicosapentaenoic acid used to treat cachexia |
| US5028440A (en) * | 1990-01-30 | 1991-07-02 | Iowa State University Research Foundation, Inc. | Method of raising meat producing animals to increase lean tissue development |
| US5087472A (en) * | 1990-01-30 | 1992-02-11 | Iowa State University Research Foundation, Inc. | Feed compositions for domestics animals containing hydroxymethylbutyrate |
| US4992470A (en) * | 1990-02-08 | 1991-02-12 | Iowa State University Research Foundation, Inc. | Method of enhancing immune response of mammals |
| US5167957A (en) * | 1990-09-06 | 1992-12-01 | Virginia Tech Intellectual Properties, Inc. | Compositions and methods for the treatment of dietary deficiencies |
| US5601860A (en) * | 1990-11-30 | 1997-02-11 | American Home Products Corporation | Corandomized fat compositions for infant formulas |
| KR100219771B1 (ko) * | 1991-03-18 | 1999-10-01 | 이치로 키타사토 | 돼지용 사료 및 이를 사용하는 돼지 사육법 |
| US5171442A (en) * | 1991-10-18 | 1992-12-15 | Nakshbendi Ghassan F | Water purification apparatus |
| US5223285A (en) * | 1992-03-31 | 1993-06-29 | Abbott Laboratories | Nutritional product for pulmonary patients |
| ES2142353T3 (es) * | 1992-09-16 | 2000-04-16 | Univ Iowa State Res Found Inc | Procedimiento para reducir los niveles de colesterol total y de colesterol asociado a lipoproteinas de baja densidad en sangre. |
| US5447732A (en) * | 1992-11-25 | 1995-09-05 | Ajinomoto Co., Inc. | High-absorption mineral-containing composition and foods |
| US5348979A (en) | 1992-12-23 | 1994-09-20 | Iowa State University Research Foundation Inc. | Method of promoting nitrogen retention in humans |
| JP2761294B2 (ja) | 1993-05-13 | 1998-06-04 | ロデルス−クロクラーン | エステル交換トリグリセリドブレンド由来のヒト母乳脂肪代用品 |
| US6136858A (en) * | 1994-01-10 | 2000-10-24 | Abbott Laboratories | Infant formula and methods of improving infant stool patterns |
| US5952314A (en) * | 1994-04-01 | 1999-09-14 | Demichele; Stephen Joseph | Nutritional product for a person having ulcerative colitis |
| US5780451A (en) * | 1994-04-01 | 1998-07-14 | Abbott Laboratories | Nutritional product for a person having ulcerative colitis |
| US5444054A (en) * | 1994-04-01 | 1995-08-22 | Abbott Labatories | Method of treating ulcerative colitis |
| US5576287A (en) * | 1994-04-29 | 1996-11-19 | Wake Forest University | Method for treating acute renal disease and failure |
| US5726146A (en) * | 1994-12-06 | 1998-03-10 | Natural Supplement Association, Incorporated | Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass |
| KR0140248B1 (ko) * | 1995-03-23 | 1998-06-15 | 한상기 | 신규한 카제인 포스포펩티드, 그것을 포함하는 카제인 및 그 제조방법 |
| DE19528461A1 (de) | 1995-08-03 | 1997-02-06 | Braun Melsungen Ag | Präparat zur Ernährung |
| US5641531A (en) * | 1995-09-28 | 1997-06-24 | Abbott Laboratories | Nutritional liquid supplement beverage and method of making same |
| JP2000509079A (ja) * | 1996-04-11 | 2000-07-18 | ロダース・クロックラーン・ビー・ブイ | 自由流動性脂肪組成物 |
| US6077828A (en) | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
| US5756469A (en) | 1996-07-26 | 1998-05-26 | Beale; Paxton K. | Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal |
| US7504376B2 (en) * | 1996-08-12 | 2009-03-17 | Natural Alternatives International | Methods and compositions for increasing the anaerobic working capacity in tissues |
| US6080788A (en) * | 1997-03-27 | 2000-06-27 | Sole; Michael J. | Composition for improvement of cellular nutrition and mitochondrial energetics |
| DE29707308U1 (de) | 1997-04-23 | 1997-06-26 | Kunz, Armin, 66450 Bexbach | Präparat zur Muskelerhaltung bzw. zur Förderung des Muskelaufbaus |
| US6660258B1 (en) | 1997-05-09 | 2003-12-09 | Pharma Pacific Pty Ltd | Oromucosal cytokine compositions and uses thereof |
| US6103764A (en) * | 1997-11-07 | 2000-08-15 | Iowa State University Research Foundation, Inc. | Method for increasing the aerobic capacity of muscle |
| US6475539B1 (en) * | 1998-05-07 | 2002-11-05 | Abbott Laboratories | Nutritionally complete low pH enteral formula |
| JP4175698B2 (ja) * | 1998-06-19 | 2008-11-05 | サントリー株式会社 | 新規なトリグリセリド及びそれを含む組成物 |
| US6031000A (en) | 1998-06-23 | 2000-02-29 | Iowa State University Research Foundation, Inc. | Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use |
| EP1100589B1 (en) | 1998-07-30 | 2005-01-19 | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | Use of propionyl l-carnitine and acetyl l-carnitine in the preparation of medicaments with anticancer activity |
| US5976550A (en) * | 1998-11-20 | 1999-11-02 | Engel; Peter H. | Dietary food supplement |
| US20010008641A1 (en) * | 1998-11-25 | 2001-07-19 | R. Douglas Krotzer | Nutritionally active composition for bodybuilding |
| US6294206B1 (en) * | 1999-04-09 | 2001-09-25 | Abbott Laboratories | Powdered human milk fortifier |
| US6291525B1 (en) * | 1999-09-08 | 2001-09-18 | Iowa State University Research Foundation, Inc. | Method for improving a human's perception of his emotional state |
| MXPA02003861A (es) * | 1999-10-18 | 2003-07-14 | Muscletech Res And Dev Inc | Suplemento alimenticio para incrementar la masa sin desarrollar y la fuerza. |
| GB9929919D0 (en) * | 1999-12-17 | 2000-02-09 | Hannah Research Inst The | Calcium phosphate nanoclusters and their applications |
| US6521591B1 (en) * | 2000-02-10 | 2003-02-18 | N.V. Nutricia | Pharmaceutical composition for muscular anabolism |
| US7250397B2 (en) * | 2000-02-23 | 2007-07-31 | Zealand Pharma A/S | Antiarrhythmic peptides |
| AU2001251449B2 (en) | 2000-04-06 | 2005-04-07 | Conlinco, Inc. | Conjugated linoleic acid compositions |
| JP4625156B2 (ja) | 2000-04-10 | 2011-02-02 | イーエヌ大塚製薬株式会社 | 癌化学療法に伴う副作用軽減剤 |
| US6420342B1 (en) * | 2000-05-08 | 2002-07-16 | N.V. Nutricia | Nutritional preparation comprising ribose and medical use thereof |
| US20050106219A1 (en) * | 2000-05-30 | 2005-05-19 | Karlheinz Bortlik | Primary composition comprising a lipophilic bioactive compound |
| IL154266A0 (en) * | 2000-08-03 | 2003-09-17 | Univ North Carolina State | Enhancement of development of oviparous species by in ovo feeding |
| ES2242770T3 (es) * | 2000-08-29 | 2005-11-16 | Lonza Ag | Procedimiento para la produccion de una mezcla granulable e hidroxicitrato de carnitina y magnesio. |
| US20030203070A1 (en) * | 2000-09-26 | 2003-10-30 | The Procter & Gamble Company | Compositions containing sorbitan monoesters |
| EP1198991B1 (en) * | 2000-10-20 | 2012-12-19 | Nutriz N.V: | Non-dairy products derived from rice |
| DE60219600T2 (de) * | 2001-02-15 | 2007-12-20 | Adeka Corp. | PRODUKTE ENTHALTEND G(b)-Glucan |
| JP3735070B2 (ja) * | 2001-03-26 | 2006-01-11 | 花王株式会社 | 容器詰乳化飲料 |
| US6620427B2 (en) * | 2001-04-24 | 2003-09-16 | Abbott Laboratories | Method for improving bone mineralization |
| US20030021877A1 (en) * | 2001-06-13 | 2003-01-30 | Cain Frederick William | Micronised fat particles |
| DE10145818C1 (de) * | 2001-09-17 | 2002-10-10 | Alfill Engineering Gmbh & Co K | Sterilisiervorrichtung mit H202-Verdampfer |
| GB2381451A (en) * | 2001-11-01 | 2003-05-07 | New Technology Res Ltd | Pharmaco-dietary preparation having nutrition-supplementing and nutrition-enhancing effect |
| JP2003137790A (ja) | 2001-11-01 | 2003-05-14 | Mie Kariyou Kk | β−２，１（β２→β１）結合連鎖フラクトースオリゴマーを含有するフラクトオリゴ糖を有効成分とする医薬 |
| EP2261312A1 (en) * | 2001-12-12 | 2010-12-15 | Martek Biosciences Corporation | Extraction and Winterization of Lipids from Oilseed and Microbial Sources |
| US7168581B2 (en) * | 2001-12-21 | 2007-01-30 | Rexam Medical Packaging Inc. | Closure for a retort processed container having a peelable seal |
| DE10163676A1 (de) | 2001-12-21 | 2003-07-10 | Phenion Gmbh & Co Kg | Verwendung von Hyperforin oder Extrakten aus Johanniskraut gegen anaphylaktische Schockzustände oder Osteoporose |
| AU2003239150A1 (en) * | 2002-04-23 | 2003-11-10 | Aventis Pharmaceuticals Inc. | 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo |
| SE0201581D0 (sv) * | 2002-05-29 | 2002-05-29 | Scandinavian Biotechnology Res | New improved acyltransferase |
| WO2004002232A1 (en) * | 2002-06-28 | 2004-01-08 | Theuer Richard C | Fat compositions for infant formula and methods therefor |
| US20040048925A1 (en) * | 2002-09-09 | 2004-03-11 | Wiley David B. | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives |
| US20040106678A1 (en) * | 2002-09-17 | 2004-06-03 | Dobbins Thomas A | Compositions for the parenteral administration of calcium and magnesium |
| WO2004035624A2 (en) * | 2002-10-14 | 2004-04-29 | Novo Nordisk A/S | Glucagon - like peptide - 2 variants |
| US7445807B2 (en) * | 2002-10-15 | 2008-11-04 | Western Holdings, Llc | Agglomerated granular protein-rich nutritional supplement |
| GB0301554D0 (en) * | 2003-01-23 | 2003-02-26 | Molecularnature Ltd | Immunostimulatory compositions |
| US7332178B2 (en) * | 2003-04-25 | 2008-02-19 | Abbott Laboratories | Stable nutritional powder containing ascorbyl palmitate |
| FR2856596B1 (fr) | 2003-06-27 | 2007-04-27 | Bioprojet Soc Civ | Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes. |
| AU2004279621A1 (en) * | 2003-10-14 | 2005-04-21 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Adenylate cyclase in the treatment and/or prophylaxis of immune-medicated disease |
| IL158555A0 (en) * | 2003-10-22 | 2004-05-12 | Enzymotec Ltd | Human breast milk lipid mimetic as dietary supplement |
| EP2311448A1 (en) * | 2003-12-24 | 2011-04-20 | N.V. Nutricia | Compositions comprising pantothenic acid or derivatives thereof and their use for stimulating appetite |
| US7696241B2 (en) * | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
| US20050215640A1 (en) | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
| US20050249650A1 (en) * | 2004-05-07 | 2005-11-10 | Fmc Technologies, Inc. | Immersion retort |
| EP1799052B2 (en) * | 2004-09-09 | 2020-01-08 | Société des Produits Nestlé S.A. | Methods for the manufacture of nutritional products having improved quality |
| US8557551B2 (en) * | 2004-09-10 | 2013-10-15 | Dsm Ip Assets B.V. | Compositions and methods for making and modifying oils |
| PL371081A1 (pl) | 2004-11-08 | 2006-05-15 | Sgp & Sons Ab | Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt |
| US8067052B2 (en) * | 2005-02-25 | 2011-11-29 | Siddharth Shastri | Nutritional composition and a container for the convenient transport and storage of the nutritional composition |
| CA2537452C (en) * | 2005-03-09 | 2013-12-24 | Abbott Laboratories | Concentrated human milk fortifier liquid |
| KR20130136013A (ko) * | 2005-04-27 | 2013-12-11 | 엔지모테크 리미티드 | 모유 지방 대체물 |
| KR20080015071A (ko) * | 2005-06-06 | 2008-02-18 | 브리스톨-마이어스스퀴브컴파니 | 저-피테이트 유아용 조제유 |
| JP2009506012A (ja) * | 2005-08-26 | 2009-02-12 | ネステク ソシエテ アノニム | 肥満患者の栄養素 |
| MY147363A (en) * | 2005-09-20 | 2012-11-30 | Nestec Sa | Water dispersible composition and method for preparing same |
| AU2006322990A1 (en) | 2005-10-07 | 2007-06-14 | Ocean Nutrition Canada Ltd. | Salts of fatty acids and methods of making and using thereof |
| EP1973426A2 (en) * | 2005-11-03 | 2008-10-01 | Southwest Immunology Inc. | Compositions for preventing and reducing delayed onset muscle soreness |
| NZ568611A (en) | 2005-12-19 | 2011-11-25 | Abbott Lab | Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type 1 and type 2 cytokine production |
| ES2346802T3 (es) * | 2006-01-31 | 2010-10-20 | Nestec S.A. | Composicion nutritiva para bebes con poco peso al nacimiento. |
| US20080119552A1 (en) * | 2006-11-17 | 2008-05-22 | Novus International Inc. | Matrix-embedded compositions having organic acids and fatty acids |
| US20080194407A1 (en) * | 2007-02-14 | 2008-08-14 | Ashmead H Dewayne | High nitrogen containing chelate compositions suitable for plant delivery |
| US20090110674A1 (en) * | 2007-10-24 | 2009-04-30 | Loizou Nicos C | Health supplement |
| US8029830B2 (en) * | 2008-04-18 | 2011-10-04 | Nuvocare Health Services Inc. | Composition and method for promoting internal health and external appearance |
| MX2010012171A (es) | 2008-05-21 | 2010-11-30 | Stokely Van Camp Inc | Bebida de recupercion a base de leche. |
| DK2381784T3 (en) | 2008-12-09 | 2018-10-22 | Metabolic Tech Inc | Nutritional intervention to improve muscle function and strength |
| JP2009155336A (ja) | 2009-03-31 | 2009-07-16 | Tsujido Chemical Corp | 治療剤 |
| US20090312419A1 (en) * | 2009-08-12 | 2009-12-17 | Kneller Bruce W | CREATINE -ßALANINATE: A NOVEL SALT FOR INCREASING ATHLETIC PERFORMANCE |
| PL217815B1 (pl) | 2009-12-14 | 2014-08-29 | Olimp Lab Spółka Z Ograniczoną Odpowiedzialnością | Napój izotoniczny z chelatami |
| CN101785566A (zh) | 2010-01-22 | 2010-07-28 | 北京康比特体育科技股份有限公司 | 一种含有hmb的运动饮料 |
| AU2011210691A1 (en) * | 2010-01-29 | 2012-07-12 | Abbott Laboratories | Nutritional emulsions comprising calcium HMB |
| TWI526161B (zh) | 2010-06-10 | 2016-03-21 | 亞培公司 | 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液 |
| US10869843B2 (en) * | 2010-11-23 | 2020-12-22 | Chemi Nutra | Method for increasing muscle mass and strength |
| CN103269695A (zh) | 2010-12-27 | 2013-08-28 | 雅培制药有限公司 | 使用β-羟基-β-甲基丁酸盐促进废用一段时期之后肌肉恢复的方法 |
| WO2012097061A1 (en) | 2011-01-13 | 2012-07-19 | Abbott Laboratories | Nutritional compositions and methods for improving skeletal muscle protein metabolism |
| WO2013056048A2 (en) | 2011-10-13 | 2013-04-18 | Abbott Laboratories | Nutritional products comprising beta-alanine |
| WO2013170189A1 (en) | 2012-05-11 | 2013-11-14 | Abbott Laboratories | Combination of beta - hydroxy - beta - methylbutyrate and beta - alanine for increasing muscle blood flow |
| WO2013188258A1 (en) | 2012-06-11 | 2013-12-19 | Abbott Laboratories | Use of hmb to improve health outcomes for hospitalized patients |
-
2006
- 2006-12-19 NZ NZ568611A patent/NZ568611A/en not_active IP Right Cessation
- 2006-12-19 NZ NZ593182A patent/NZ593182A/xx not_active IP Right Cessation
- 2006-12-19 BR BRPI0620083-4A patent/BRPI0620083A2/pt not_active IP Right Cessation
- 2006-12-19 WO PCT/US2006/048303 patent/WO2007075605A2/en active Application Filing
- 2006-12-19 ES ES06845745.6T patent/ES2548432T3/es active Active
- 2006-12-19 JP JP2008547409A patent/JP5227182B2/ja not_active Expired - Fee Related
- 2006-12-19 RU RU2008129605/15A patent/RU2469719C2/ru not_active IP Right Cessation
- 2006-12-19 EP EP06845745.6A patent/EP1968564B1/en not_active Expired - Fee Related
- 2006-12-19 EP EP09156851.9A patent/EP2082738B1/en not_active Expired - Fee Related
- 2006-12-19 AU AU2006331950A patent/AU2006331950A1/en not_active Abandoned
- 2006-12-19 CA CA2632262A patent/CA2632262C/en not_active Expired - Fee Related
- 2006-12-19 US US11/641,978 patent/US8778992B2/en not_active Expired - Fee Related
- 2006-12-19 CN CN2011100849630A patent/CN102225060A/zh active Pending
- 2006-12-19 TW TW095147808A patent/TWI424840B/zh not_active IP Right Cessation
- 2006-12-19 CN CN2006800479363A patent/CN101374509B/zh not_active Expired - Fee Related
- 2006-12-19 ES ES09156851.9T patent/ES2548305T3/es active Active
- 2006-12-19 MY MYPI20082097A patent/MY180733A/en unknown
-
2008
- 2008-06-16 EC EC2008008539A patent/ECSP088539A/es unknown
- 2008-06-18 CR CR10085A patent/CR10085A/es unknown
- 2008-06-18 ZA ZA200805297A patent/ZA200805297B/xx unknown
- 2008-06-19 SV SV2008002948A patent/SV2009002948A/es unknown
-
2011
- 2011-08-12 RU RU2011133891/15A patent/RU2011133891A/ru not_active Application Discontinuation
-
2012
- 2012-01-11 US US13/347,757 patent/US20120178811A1/en not_active Abandoned
- 2012-01-11 US US13/347,750 patent/US8796333B2/en not_active Expired - Fee Related
- 2012-01-11 US US13/347,774 patent/US20120177744A1/en not_active Abandoned
-
2013
- 2013-01-24 JP JP2013010874A patent/JP5696168B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011133891A (ru) | СПОСОБ ЛЕЧЕНИЯ АСТМЫ (ВАРИАНТЫ) И СПОСОБ СНИЖЕНИЯ РИСКА РАЗВИТИЯ ИНФЕКЦИЙ ПОСРЕДСТВОМ β-ГИДРОКСИ-β-МЕТИЛБУТИРАТА | |
| Lönnerdal | Nutritional roles of lactoferrin | |
| Rhule et al. | Panax notoginseng attenuates LPS-induced pro-inflammatory mediators in RAW264. 7 cells | |
| RU2128056C1 (ru) | Способы и препараты для лечения заболеваний интерфероном, характеризующиеся сниженными побочными эффектами | |
| DE60127457D1 (de) | Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen | |
| Aviles et al. | Active hexose correlated compound enhances the immune function of mice in the hindlimb-unloading model of spaceflight conditions | |
| Rochell et al. | Effects of dietary soybean meal concentration on growth and immune response of pigs infected with porcine reproductive and respiratory syndrome virus | |
| ATE204178T1 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
| Michele et al. | Vitamin supplements in the Era of SARS-Cov2 pandemic | |
| Samad et al. | Fat-soluble vitamins and the current global pandemic of COVID-19: evidence-based efficacy from literature review | |
| JP3392668B2 (ja) | ゴマリグナン物質とビタミンｅ類の強化卵、強化卵の製造法、および強化卵に基づく健康食品 | |
| JP6675752B2 (ja) | 腸内Ｂｌａｕｔｉａ ｃｏｃｃｏｉｄｅｓ増殖刺激剤 | |
| EP3174548B1 (en) | Marine peptides and fish nucleotides, compositions and uses thereof for reducing blood glucose | |
| ATE48759T1 (de) | Behandlung von anfaellen und hierfuer nuetzliche pharmazeutische zusammensetzungen. | |
| US3347742A (en) | 2-(4-cyclohexylcyclohexyl)-3-hydroxy-1, 4-naphthoquinone in controlling coccidiosis in poultry | |
| Sarker et al. | Keyhole limpet hemocyanin augmented the killing activity, cytokine production and proliferation of NK cells, and inhibited the proliferation of Meth A sarcoma cells in vitro | |
| JP2005330213A (ja) | 酸化ストレス抑制剤 | |
| Wu et al. | Major royal-jelly proteins intake modulates immune functions and gut microbiota in mice | |
| CN107029214A (zh) | 一种调节肠道微生物的组合物及其制备方法 | |
| Kobayashi et al. | Dietary supplementation of soybean kunitz trypsin inhibitor reduces lipopolysaccharide-induced lethality in mouse model | |
| Meydani et al. | Vitamin E and immune response in the aged | |
| CN109620823A (zh) | 一种Hypholomine B在制备免疫激活剂中的应用 | |
| KUROKI et al. | Antitumor effect of recombinant murine interferon-β against mouse malignant glioma | |
| US20230285471A1 (en) | Compositions and Methods for Treating Viral Infection | |
| PT1100463E (pt) | Novas formulacoes injectaveis contendo ramoplanina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20140813 |